






























1Oral Science International 12 (2015) 15–21
Contents lists available at ScienceDirect
Oral  Science  International
j ourna l h om epage: www.elsev ier .com/ locate /os i
riginal  Article
ssociation  of  oral  tumor  suppressor  gene  deleted  in  oral  cancer-1
DOC-1)  in  progression  of  oral  precancer  to  cancer
tul  Katarkara, Leelavati  Patelb,  Sanjit  Mukherjeea,1, Jay  Gopal  Rayb,
allab  Kanti  Haldarc,  Keya  Chaudhuria,∗
Molecular & Human Genetics Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S.C. Mullick Road, Kolkata 700032, India
Department of Oral Pathology, Dr. R. Ahmed Dental College & Hospital, Kolkata 700014, India
Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 29 August 2014
eceived  in revised form
8 November 2014





ral  premalignant condition
ral squamous cell carcinoma
a  b  s  t  r  a  c  t
Introduction:  Deleted  in  oral  cancer-1  (DOC-1),  a highly  conserved  tumor  suppressor  gene,  encodes  a
speciﬁc  cyclin-dependent  kinase  2-associated  protein  1 (p12DOC-1). The  protein  DOC-1  arrests  the  cells
in  the  G1 phase  of  the  cell  cycle  and regulates  DNA  replication  in  the S phase  of  the cell  cycle.  It is  known
that  DOC-1  is  downregulated  in  head  and neck  cancer.  Hence,  the  aim  of the  study  was  to  analyze  the
messenger  RNA  (mRNA)  expressions  of  DOC-1  in patients  with  oral  lichen  planus  (OLP),  leukoplakia
(LPK),  oral  submucous  ﬁbrosis  (OSF),  and  oral squamous  cell  carcinoma  (OSCC)  in comparison  to  normal
control  subjects,  and  these  were  correlated  with  differential  oral  habits  and  duration  of exposure.
Materials and  methods:  Semiquantitative  one-step  reverse  transcriptase  polymerase  chain  reaction
(RT-PCR)  was  used  to  assess  the potential  role  of  DOC-1  in  differential  oral conditions.
Results: The  expression  of DOC-1  at the  transcriptional  level was found  to  be  consistently  reduced  (39.13%)
or  non-detectable  (60.87%)  in OSCC  cases;  LPK  cases  also  showed  reduced  (26.19%)  or non-detectable
(59.52%)  DOC-1  expression,  and overexpression  of DOC-1  was observed  in  patients  with  OSF  (42.3%)  and
OLP  (35.29%)  as  compared  to  the  normal  control  groups.  A marked  reduction  in DOC-1  expression  was
observed  in patients  who  smoke  bidi  and  chew  tobacco  compared  to patients  who  smoke  cigarettes  and
chew  pan. An overall  reduced  expression  of  DOC-1  with  an  increase  in  the  duration  of exposure  was
observed.
Conclusions:  The  overexpression  of  DOC-1  in oral  premalignant  disease  groups  with  reduced  or  loss  of
expression  in OSCC  groups  suggests  its  association  in  the  progression  of  oral  carcinogenesis,  suggesting
DOC-1  to be an  important  prognostic  indicator  for  oral  cancer.
 Japan©  2014
. Introduction
Oral cancer (OC) has high mortality and morbidity rates as
ost patients are presented for treatment at late stages of the
ancer. It has been well established that oral squamous cell carci-
oma (OSCC) manifests as several biochemical, cellular, and clinical
hanges in the affected epithelium of the oral mucosa. Sometimes,
his is preceded by white, red, or mixed mucosal changes, and
hese are known as oral potentially malignant disorders (OPMDs)
uch as oral lichen planus (OLP), leukoplakia (LPK), and oral
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submucous ﬁbrosis (OSF) [1–3]. The malignant transformation rate
for OLP was 1.1–1.63% [4,5], LPK 0.13–17.9% [6,7], and OSF 7.6%
[8]. Habitual usage of areca quid/pan, bidi/cigarettes, and com-
mercially available smokeless form of products such as gutkha,
pan masala, khaini, and supari, has been considered as the main
etiological factor for OPMDs and OC [9,10]. Cell cycle machin-
ery deregulation is a fundamental hallmark of cancer progression
[11]. Deregulations in cell cycle regulatory protein are common in
oral carcinogenesis [12]. The abrogation of cell cycle regulatory
proteins such as retinoblastoma tumor suppressor protein (pRB),
cyclin D1, cyclin-dependent kinase (CDKs), and CDK inhibitors
(p12WAF1/CIP1, p27KIP1, and p16INK4a) occurs in response to extracel-
lular/intracellular stress and DNA damage, and these proteins ﬂock
on the cell cycle machinery and stimulate oral carcinogenesis [12].
Recently, cell cycle regulatory proteins such as CDK2AP1 (cyclin-
dependent kinase 2-associated protein 1; p12DOC-1) corresponding
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o be extensively involved in the pathogenesis of several can-
ers. DOC-1 is a highly conserved tumor suppressor identiﬁed
y normal hamster oral keratinocytes by suppression subtractive
ybridization experiments [13]. DOC-1 is ubiquitously expressed
nd highly conserved; the gene is mapped on chromosome 12q24,
nd a complementary DNA (c-DNA) 1.6 kilobase pairs (kb) in length
as been cloned from humans, mice, and hamsters [13–15]. DOC-
 was revealed to have three recognized binding targets DNA
olymerase alpha/primase [16], DOC-1R (deleted in oral cancer
-related; CDK2AP2) [17], and CDK2 [18]. The interaction of DOC-
 with DNA polymerase alpha/primase, important in cell cycle
egulation and initiation of de novo DNA replication, negatively
egulates DNA replication at the initiation step and not the elonga-
ion phase [16]. DOC-1R/DOC-1 is a substrate of mitogen-activated
rotein kinase (MAPK) and is important in microtubule associa-
ion during meiotic maturation [17]. DOC-1 interacts with the free
onomeric non-phosphorylated form of CDK2 [18], which regu-
ates the G1/S phase transition of the cell cycle through complexes
ith cyclins A and E [19]. DOC-1 inhibits CDK2 kinase activities by
equestering the monomer (inactive) pool of CDK2 by preventing
he formation of complexes with cyclins A and E and by targeting
DK2 for the proteasome degradation pathway on overexpression
f DOC-1 in cells [18]. Hence, DOC-1 repressed DNA replication
y inhibition of DNA polymerase alpha/primase and CDK2 inhi-
ition. Recently, DOC-1 has been shown to play important roles
n transforming growth factor beta (TGF-)-mediated growth sup-
ression independent of p15INK4B, and p12CIP1 signiﬁes a speciﬁc
DK2 inhibitor [20]. Isotope labeling studies revealed that DOC-1
s also a subunit of the Mi-2/NuRD (nucleosome remodeling and
istone deacetylase) complex and may  be involved in epigenetic
ene regulation [21].
The  expression of the DOC-1 gene was absent or reduced in
he malignant human oral keratinocyte and transformed hamster
odel [14,15]. DOC-1 is constitutively expressed in normal human
issues, and it interacts with cell cycle regulatory elements [15,16].
he ectopic expression of DOC-1 is associated with decreased
ellular CDK2-associated kinase activity in human embryonic kid-
ey 293 cells and it elevates the number of apoptotic cells in
he transfected malignant hamster keratinocyte model, implying
 possible role for CDK2AP1 in apoptotic pathways [18,22]. These
arly studies suggested an important role of DOC-1 in carcinogen-
sis. Recently, several studies have reported negative or decreased
OC-1 expression in gastric cancer tissue, and this was  highly
orrelated with more advanced tumor stage and invasion [23],
isk of lymph node metastases, and decreased survival in patients
ith OSCC [24]. Similar reports were observed from many can-
er types including prostate cancer [25], esophageal carcinoma
26], breast cancer [27], colorectal cancer [28], and lung cancer
29].
In the present study, the messenger RNA (mRNA) expression
f DOC-1 in patients with OLP, LPK, OSF, and OSCC in comparison
o normal control subjects has been investigated and correlated to
ifferential oral habits. In addition, the correlation of DOC-1 mRNA
xpression with exposure was investigated to determine the role
f the DOC-1 gene in the early detection of cancer progression and
ral carcinogenesis.
.  Materials and methods
.1.  Patient and controlThe  clinically and histopathologically conﬁrmed patients with
LP, LPK, OSF, and OSCC were selected from the outpatient depart-
ent of Dr. R. Ahmed Dental College & Hospital in Kolkata, India.
 total of 195 consecutive patients with OLP (n = 17), LPK (n = 42),ernational 12 (2015) 15–21
OSF  (n = 52), and OSCC (69) and healthy normal volunteers (con-
trols) (n = 15) were recruited to study the mRNA expression of
DOC-1 in the biopsy tissue. Detailed oral examination was con-
ducted by a trained clinical oral pathologist. Healthy volunteers
without oral habit or oral habit for <6 month with a normal oral
epithelium were included. Patients having oral habits for >6 months
along with precancerous or cancerous lesions were included in the
study. The demographic parameters were recorded using a detailed
questionnaire. Patients suffering from infectious/contagious dis-
ease, intractable medical or radiological abnormality, other white
patches such as in candidiasis, or suffering from scleroderma were
excluded from the study. The biopsy specimen was collected from
the cheek in the control group and depending upon the location of
the lesion in precancer and cancer. In OLP, sites with white stria-
tions, white papules, white plaques, erythema, erosions, or blisters
affecting predominantly the buccal mucosa were selected. In LPK,
sites with white or white-and-red lesions that may be either irreg-
ularly or uniformly ﬂat and thin and nodular or exophytic having a
wrinkled or corrugated surface with a consistent texture through-
out were selected. In OSF, sites with tough, leathery texture of
the mucosa, blanching of mucosa (persistent, white, marble-like
appearance, which may  be localized, diffuse, or reticular), and quid-
induced lesion (ﬁne, white, wavy, parallel lines that do not overlap
or crisscross, are not elevated, and radiate from a central ery-
thematous area) were selected. In OSCC, sites with red or white,
painless, nonhealing, indurated ulcers were selected. The patients
with OSCC were descriptively categorized as well-differentiated
(grade I), moderately differentiated (grade II), poorly differenti-
ated (grade III), and undifferentiated (grade IV) [30]. The study
was approved by an ethical review committee of the institute, and
informed consent was obtained from all participating patients and
healthy volunteers.
2.2.  Sample collection, RNA extraction, and reverse transcriptase
polymerase chain reaction
Oral  biopsy tissue from the precancerous and cancerous site
was washed thrice with sterile 1× phosphate-buffered saline
(PBS) and transferred into a 1.5-ml Eppendorf micro-centrifuge
tube containing 1 ml  of TRIzol reagent (Invitrogen, Grand Island,
NY, USA). The sample tubes were stored at −20 ◦C until fur-
ther usage. The total RNA was isolated from the whole biopsy
tissue specimen (containing both epithelium and connective
tissue) using TRIzol (Invitrogen) following the manufacturer’s
instructions. To the RNA pellet, 40 l of diethyl pyrocarbonate
(DEPC)-treated water was  added to ensure complete dissolu-
tion of RNA into the solution. A reverse transcriptase polymerase
chain reaction (RT-PCR) was  performed with 1 g of RNA using
the one-step RT-PCR kit (QIAGEN, Valencia, CA, USA). DOC-1
obtained from the biopsy tissue was ampliﬁed using a forward
primer, 5′-ATGGCAACGTCTTCACAGTACC-3′, and a reverse primer,
5′-CAGTCCTCTAGCGTGAATGATG-3′. The ampliﬁcation conditions
were as follows: reverse transcription at 50 ◦C for 30 min, the
initial PCR activation step at 95 ◦C for 15 min, 35 cycles of denat-
uration at 95 ◦C for 30 s, annealing at 62 ◦C for 30 s, extension
at 72 ◦C for 1 min, and the ﬁnal extension at 72 ◦C for 10 min.
Glyceraldehyde-3-phosphate dehydrogenase (GADPH) used as an
internal control for tissue expression was  ampliﬁed with the for-
ward primer 5′-ATGGGGAAGGTGAAGGTCGG-3′ and the reverse
primer 5′-GGATGCTAAGCAGTTGGT-3′. The ampliﬁcation condi-
tions were as follows: 35 cycles of denaturation at 95 ◦C for 30 s,
annealing at 61 ◦C for 30 s, and extension at 72 ◦C for 1 min. The
ampliﬁed RT-PCR products were subjected to electrophoresis on
2% agarose gels and stained with ethidium bromide. The gel was
placed in a Gel Doc system (PerkinElmer, Waltham, MA,  USA) for
visualization.
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Fig. 1. DOC-1 mRNA expression. The representation of oral precancerous conditions (OLP, LPK, and OSF) and OSCC, the histological characteristics, and DOC-1 mRNA










Ysed as an internal control for the quantiﬁcation of DOC-1 mRNA expression.
.3. Statistical analysis
GraphPad  Prism software (San Diego, CA, USA) was used
or statistical analysis. The relative intensity of DOC-1 mRNA
xpression from the image of RT-PCR bands was calculated
gainst the internal control GAPDH using an ImageJ® analy-
is system (software, National Institutes of Health, Bethesda,
D, USA). A comparison of the expression of DOC-1 mRNA
able 1
emographic characteristics and different oral habit exposures in the study population.
Parameter Normal OLP 
n = 195 n = 15 n = 17 
Age  (yr) 29.46 ± 7.03 41.35 ± 12.17 
Sex
Female  6 (40.00%) 4 (23.52%) 
Male 9 (60.00%) 13 (76.47%) 
Exposure (yr) – 11.35 ± 6.43 
Habit
Areca  – – 
Bidi  – 2 (11.76%) 
Cigarette – 10 (58.82%) 
Pan  – – 
Tobacco – 5 (29.42) 
r; years, Areca; only having habit of areca nut chewing, Pan; includes mixture of betel lebetween  the OLP, LPK, OSF, and OSCC patient groups and the con-
trol group was performed using nonparametric Mann–Whitney
tests. A comparison of the expression of DOC-1 between
the differential oral habits was  performed using nonparamet-
ric Mann–Whitney tests. The correlations of DOC-1 mRNA
expression with the duration of exposure were analyzed using
Spearman’s rank test. A p-value <0.05 was set as statistically
signiﬁcant.
LPK OSMF OSCC
n = 42 n = 52 n = 69
47.66 ± 10.91 28.67 ± 9.41 53.87 ± 11.14
8 (19.04%) 11 (21.16%) 26 (37.68%)
34 (80.96%) 41 (78.84%) 43 (62.32%)
19.92 ± 12.43 6.11 ± 5.40 20.23 ± 13.27
– 40 (76.92%) 7 (10.14%)
17 (40.4%) – 16 (23.18%)
6 (14.28%) – 3 (4.35%)
8 (19.05%) 12 (23.08%) 19 (27.53%)
11 (26.19%) – 24 (34.78%)
af, areca nut, and slaked lime, and may contain tobacco.
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Fig. 2. Quantitative analysis of DOC-1 mRNA expression. (A) The horizontal scat-
tered plot representation of log2 (fold change) in the DOC-1 mRNA expression in
precancer (OLP, LPK, and OSF) and OSCC. The non-detectable or loss of expression
(zero)  and overexpression (positive) and reduced expression (negative) of DOC-1
mRNA was shown. Log2 (relative DOC-1 mRNA expression of case/average of relative
DOC-1 mRNA expressions of control). (B) The vertical scattered plot representation
of  DOC-1 mRNA expression in precancer (OLP, LPK, and OSF) and cancer patients
compared  to normal. “***” shows the level of signiﬁcance with p-value <0.0001. (C)
The vertical scattered plot representation of DOC-1 mRNA expression in differential
oral  habits (areca, bidi, cigarette, pan, and tobacco). “*,” “**,” and “***” shows the
level of signiﬁcance with p-value <0.05, <0.001, and <0.0001, respectively.
Table 2
The  DOC-1 mRNA expression analysis in precancer and cancer patients compared to norm
Clinical condition N DOC-1 mRNA
Expressionb
Normal 15 15 (100.00%) 
OLP  17 13 (76.47%) 
LPK  42 17 (40.47%) 
OSMF  52 44 (84.61%) 
OSCC  69 27 (39.13%) 
Sum  () 195 101 (56.11%)a
a The population of precancer and cancer.
b The overall DOC-1 mRNA expression, including both overexpression or reduced exprernational 12 (2015) 15–21
3. Result
A representative clinical presentation of control subjects and
precancer and cancer patients along with DOC-1 mRNA expression
is described in Fig. 1. Demographic parameters such as age, sex,
and duration of exposure to deleterious oral habits are presented in
Table 1. Of the total number of participants in the study, 28.2% were
female and 71.8% were male. All participants of the precancer and
cancer group had a history of deleterious oral habits with varying
durations of exposure. The mean durations of exposure (±standard
deviation (SD) in years) of deleterious oral habits among the
study patients as observed were as follows: OLP 11.35 ± 6.43, LPK
19.92 ± 12.43, OSF 6.11 ± 5.40, and OSCC 20.23 ± 13.27 (Table 1).
The  overexpression and reduced expression of DOC-1 mRNA
in the lesion site was calculated as follows: log2 (relative DOC-
1 mRNA expression of case/average of relative DOC-1 mRNA
expression of control). This results in a positive value for the over-
expression and a negative value for the reduced DOC-1 mRNA
expression. The non-detectable level of DOC-1 mRNA was des-
ignated as a loss of DOC-1 expression (Fig. 2A). The distribution
of DOC-1 mRNA expression in the precancer and cancer group
compared to the normal control group, among the DOC-1 mRNA-
expressing individuals, is shown in Fig. 2B. DOC-1 mRNA expression
was detected in all biopsy tissues of the control group (n = 15). Inter-
estingly, LPK and OSCC showed a remarkable loss of DOC-1 mRNA
expression in ∼60% of cases each. Of the total number of cases,
76.41% and 84.61% retained the DOC-1 mRNA expression in the
form of either overexpression or reduced expression in OLP (35.29%
and 41.17%) and OSF (42.30% and 42.30%), respectively (Table 2).
This suggested that the rate of loss of DOC-1 mRNA expression was
more frequent in the LPK and OSCC cases than OLP and OSF.
The  mean ± SD DOC-1 mRNA expression was  signiﬁcantly
reduced (p-value <0.0001) in patients with OSCC (0.357 ± 0.1)
compared to control subjects (0.97 ± 0.28) and patients with OLP
(0.90 ± 0.44), LPK (0.85 ± 0.51), and OSF (0.94 ± 0.49) (Table 3)
(Fig. 2B). However, no signiﬁcant difference in DOC-1 mRNA
expression between healthy control subjects without with oral
habits (n = 15, 0.91 ± 0.38, p = 0.49) was  observed (data not shown).
The total group of patients could be further stratiﬁed into
the overexpression or reduced DOC-1 mRNA expression group.
The mean ± SD of DOC-1 mRNA expression in overexpressing
patients with OLP (1.33 ± 0.16), LPK (1.51 ± 0.0.11), and OSF
(1.40 ± 0.21) was signiﬁcantly higher with p-value being 0.009,
0.002, and <0.0001, respectively, compared to the control group.
The mean ± SD of DOC-1 mRNA expression in patients of the
reduced expression group with OLP (0.54 ± 0.2), LPK (0.48 ± 0.13),
OSF (0.49 ± 0.12), and OSCC (0.35 ± 0.10) was  signiﬁcantly lower
with p-value being 0.004, <0.0001, <0.0001, and <0.0001, respec-
tively, compared to the control group.
Moreover, DOC-1 mRNA expression in patients with OSCC was
further distributed according to Broders’ classiﬁcation (Table 4).
al control subjects.
Loss Overexpression Reduced expression
0 (0.00%) – –
4 (23.53%) 6 (35.29%) 7 (41.17%)
25 (59.52%) 6 (14.85%) 11 (26.19%)
8 (15.38%) 22 (42.30%) 22 (42.30%)
42 (60.87%) 0 (0.00%) 27 (39.13%)
79 (43.89%)a 34 (18.89%)a 67 (37.22%)a
ession of DOC-1 mRNA.
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Table  3
The  mean ± SD DOC-1 m-RNA expression analysis in precancer and cancer patients compared to normal control subjects.
N Mean ± SD (DU) DOC-1 overexpression DOC-1 reduced expression p-Value#
Normal 15 0.9742 ± 0.2864 – – <0.0001
OLP 13 0.9083 ± 0.4475 1.334 ± 0.1653** 0.5437 ± 0.2045** <0.0001
LPK 17 0.8503 ± 0.5176 1.513 ± 0.0.1100** 0.4803 ± 0.1337*** <0.0001
OSMF 44 0.9416 ± 0.4981 1.403 ± 0.2105*** 0.4900 ± 0.1290*** <0.0001
OSCC 27 0.3567 ± 0.1069 – 0.3567 ± 0.1069*** –
** The level of signiﬁcance having p-value <0.001.
*** The level of signiﬁcance having p-value <0.0001.
# The p-value obtained after comparing the DOC-1 mRNA expression of OSCC with normal and precancer group using nonparametric Mann–Whitney test.
Table 4
The  distribution and DOC-1 mRNA expression analysis in patients with OSCC according to Broders’ classiﬁcation.
Broders’ classiﬁcation N DOC-1 mRNA expression
Loss Reduced expression
Well differentiated (GI) 55 (79.71%) 28  (40.57%) 27  (39.13%)
Moderately  differentiated (GII) 7 (10.14%) 7 (10.14%) 0 (0.00%)






























TUndifferentiated  (GIV) 0 (0.00%) 
Sum  () 69 
nterestingly, in patients with moderately and poorly differentiated
SCC, a complete loss of DOC-1 mRNA expression was  observed,
hereas patients with well-differentiated OSCC demonstrated a
oss of (40.57%) and reduced (39.13%) DOC-1 mRNA expression.
his suggested a loss of DOC-1 mRNA expression with progression
f OSCC.
The analysis of DOC-1 mRNA expression with respect to oral
abits was conducted, and, interestingly, we observed that those
ith bidi smoking and tobacco chewing oral habits showed signif-
cantly reduced expression (0.45 ± 0.26 and 0.58 ± 0.4) compared
o the control group (p-value <0.0001 and <0.05, respectively).
mong bidi- and tobacco-habituated patients, 45% show signif-
cantly reduced DOC-1 mRNA expression and 55% show loss of
OC-1 mRNA expression. The distribution of DOC-1 mRNA expres-
ion with different oral habits is shown in Fig. 2C. Similarly, patients
abituated to bidi show a signiﬁcantly reduced expression of DOC-
mRNA compared to patients habituated to areca nut (0.94 ± 0.5)
nd cigarettes (0.94 ± 0.54) (with p-values of 0.0004 and 0.0168,
espectively) (Table 5). A signiﬁcant reduction in DOC-1 mRNA
xpression was observed in tobacco users (0.58 ± 0.4) compared
o those who chewed areca (Fig. 2C).
Further, to determine the correlation, if any, between the expo-
ure to deleterious habits and DOC-1 mRNA expression in the
recancer and cancer groups, nonparametric Spearman correla-
ion analysis was performed (Fig. 3A–D). A signiﬁcantly higher
egative correlation was observed in OLP (r = −0.92, p < 0.0001),
PK (r = −0.79, p < 0.0001), OSF (r = −0.62, p < 0.0001), and OSCC
r = −0.44, p < 0.0001) in the reduced DOC-1 mRNA expression
roup. Overall, we found a highly signiﬁcant negative correlation
r = −0.43, p < 0.0001) between the exposure period and DOC-1
able 5
he  mean ± SD DOC-1 m-RNA expression analysis with differential oral habits.
Habit N Mean ± SD (DU)
Areca 36 0.9395 ± 0.5002
Bidi  16 0.4524 ± 0.2616***
Cigarette 12 0.9381 ± 0.5459
Pan  19 0.7474 ± 0.5116
Tobacco  18 0.5859 ± 0.4001*
Sum () 101
* The level of signiﬁcance having p-value <0.05.
*** The level of signiﬁcance having p-value <0.0001.0 (0.00%) 0 (0.00%)
42 (60.87%) 27 (39.13%)
mRNA expression (Fig. 3E), but no signiﬁcant correlation (r = 0.21,
p = 0. 22) was found between the overexpression of DOC-1 mRNA
and the duration of exposure (Fig. 3F).
4. Discussion
Understanding the molecular mechanism behind the malig-
nant transformation of the oral precancerous condition into OC
is critical. The development of therapeutic modalities and iden-
tiﬁcation of an early diagnostic marker is the need of the hour to
minimize the malignancy transformation rate. Fundamental stud-
ies have unfolded the molecular mechanism behind the molecular
control and functional regulation of the cell cycle in the pathogen-
esis of cancer. However, the critical role of certain proteins, which
may have a distinct role in the protection or pathogenesis of cancer
and may  serve as potentially good biomarkers for early detection,
remains to be elucidated. In the present study, we reported the dif-
ferential mRNA expression of the tumor suppressor deleted in oral
cancer-1 (DOC-1) gene, which has not been reported previously in
relation to the precancerous conditions of OSF, OLP, and LKP, and
differential oral habits. Clinically, a decrease in DOC-1 expression in
OSCC and other forms of cancers has been found to correlate with
its potential role in malignancy [25–29], whereas in vivo studies
have shown that the overexpression of DOC-1 in mouse and ham-
ster model of OC, and HCPC-1 cells signiﬁcantly induced antitumor
response, growth suppression, and an increase in apoptosis and
antiproliferative effect [22,31]. In the present study, a loss of DOC-
1 mRNA expression was  observed in 61% of patients with OSCC
and a reduced DOC-1 mRNA expression in 39% of patients. The
gradual loss of DOC-1 mRNA expression from the well- to undif-
ferentiated stage of OSCC may  have the prognostic and prediction
to aggressiveness of lesion.
LPK  is considered as the potentially malignant disorder of
the oral cavity. Etiological risk factors include cigarette and bidi
smoking, tobacco chewing, alcohol abuse, vitamin deﬁciency, and
infections [7]. In the present study, nearly 85% of patients with LPK
showed either loss of or reduced DOC-1 mRNA expression. A sim-
ilar decreased expression was also observed in patients with LPK
by Wenghoefer et al. [32] and Shintani et al. [33]. However, a sim-
ilar pattern of DOC-1 mRNA expression was observed in LPK as
that of OSCC. Hence, the higher malignancy transformation rate of
LPK into OSCC can be further correlated in terms of DOC-1 mRNA
expression.

















rig. 3. Nonparametric Spearman correlation analysis. Correlation between the DO
LP  (A), LPK (B), OSF (C), OSCC (D), overall (E), and only DOC-1 overexpression (F). 
OSF is a chronic premalignant disease of the oral mucosa
ssociated with the areca nut-chewing habit. This condition is
haracterized by inﬂammation and progressive accumulation of
ollagen ﬁbers in the lamina propria and deeper connective tis-
ue followed by stiffening of the mucosa resulting in difﬁculty
n mouth opening called “trismus” [34]. The epidemiological evi-
ence suggests that chewing of areca nut is the major risk factor for
SF development [8,10], but not all chewers developed OSF. This
mplies that there must be certain factors such as genetic predispo-
ition or epigenetics that may  explain such individual variability.
n the present study, areca nut chewers showed unregulated and
ownregulated distribution of DOC-1 mRNA expression. This sug-
ested that there must be certain other factors along with oral
abits playing a major role in the modulation of DOC-1 expression.
he overexpression of DOC-1 mRNA in the case of OSF could be cor-
elated with its protective action or it is delayed in the malignantRNA expression in tissue and exposure to deleterious oral habits of patients with
earman correlation coefﬁcient (r) and p-value were indicated.
transformation of OSF into OSCC, and it may  act as an indicative
marker.
OLP is a mucocutaneous disease due to nonspeciﬁc inﬂam-
mation leading to intense destruction of the basal layer of the
epithelium [35]. It has often been questioned whether patients with
OLP have a hereditary predilection to malignant transformations.
However, the risk of malignant transformation in OLP is lower than
in LPK and OSF. Smoking has been considered to have the highest
prevalence in initiating OLP, also associated with tobacco and areca
nut chewing [35]. In the present study, overexpression of DOC-1
mRNA was observed in 35% of patients with OLP. This could be
explained as the protective response toward the stressed induced
in the mucosa of OLP due to oral habits.
Attempts were also made to correlate DOC-1 mRNA expression
with the duration of exposure to deleterious oral habits. A sig-
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o an increase in the duration of exposure especially in patients
sing tobacco (smoking/smokeless) indicates the effect of deleteri-
us oral habits on the development of oral carcinogenesis. Notably
n the initial stage of exposure to oral habits, DOC-1 mRNA expres-
ion was upregulated in certain precancer patients, which has been
bserved to gradually decrease in patients having more than 10
ears of oral habit. These observations may  emphasize the tumor-
uppressing action of DOC-1 or the protective role of DOC-1 against
he oncogenic stimulus at the initial stages, which has also been
emonstrated in several other in vitro studies [13,22].
Winter et al. have shown the reduction of DOC-1 mRNA expres-
ion in the biopsy tissue of irritation ﬁbromas (0.7), LPK (0.2),
nd OSCC (not traceable) compared to healthy gingiva (baseline
) and its expression by immunohistochemistry (IHC) study on the
ame sample [36]. This study further suggested the tight regula-
ion between DOC-1 mRNA and protein expression as shown by
HC. Moreover, the RT-PCR is the most sensitive method of mRNA
etection even at small amounts of mRNA. In the early diagnosis of
recancerous conditions or to detect the aggressive nature of can-
er, the RT-PCR method has frequently been used. Therefore, the
resent study has been limited to analysis of DOC-1 mRNA expres-
ion using RT-PCR analysis, and it warrants further study at the
ranslational level along with additional biomarkers to make DOC-1
 better indicative marker for oral precancer and OSCC.
To  conclude, we believe our observation of the differential
xpression of DOC-1 mRNA in patients with OLP, LPK, OSF, and
SCC in comparison to controls is signiﬁcant given to its established
ole in growth control, cell cycle kinetics, and DNA replication
15,16,18,20]. We  anticipate that a further study regarding the role
f DOC-1 in cell cycle regulation and apoptosis may  partially explain
he ﬁne mechanism between the premalignant and malignant state
f a cell. Similarly, the parameter or the molecular event that
ontrols the upregulation and downregulation of DOC-1 expres-
ion response to stress is still elusive; therefore, further research
s required. The present study further proposes the DOC-1 as a
romising marker at least to differentiate the state of a premalig-
ant tissue and further assists in developing novel prevention and
reatment strategies.
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